PBT434 presented at 13th International AD/PD Conference
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Half Year Accounts
- Business Update
- S&P DJ Indices Announces March Quarterly Review
- S&P DJ Indices Announces March Quarterly Rebalance
- Prana provides regulatory update for PBT2
Later from Alterity Therapeutics
- PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
- Prana commences research collaboration with Takeda
- Appendix 4E and Annual Report
- Notice of Meeting/ Proxy Form
- Prospectus Supplement
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics